AI-powered
podcast player
Listen to all your favourite podcasts with AI-powered features
Summary
Transcript
Episode notes
Bluebird bya just got approval for zenteglo, a gen therapy currently approved for bata thalsemia. It looks like it also works in sickle cells, so they maye get a subsequent approval in that that's not a crisper drug, it's a gean therapy. They've priced it at two point eight million dollars. Now, their argument is that the lifetime cost of treating somebody with bata thallemia with all the blood transfusions that they'll need are something around six point four million dollars. An hospitalization on an emergency basis is something around 6 point 4 million dollars. So maybe that's not so bad. Maybe that's one way to
Get the Snipd
podcast app
Unlock the knowledge in podcasts with the podcast player of the future.
AI-powered
Discover
highlights
Listen to the best highlights from the podcasts you love and dive into the full episode
Save any
moment
Hear something you like? Tap your headphones to save it with AI-generated key takeaways
Share
& Export
Send highlights to Twitter, WhatsApp or export them to Notion, Readwise & more
AI-powered
podcast player
Listen to all your favourite podcasts with AI-powered features
Discover
highlights
Listen to the best highlights from the podcasts you love and dive into the full episode